ANGIOTENSIN CONVERTING ENZYMES (ACE) INHIBITORS MARKET ANALYSIS

Angiotensin Converting Enzymes (ACE) Inhibitors Market, By Drugs (Benazepril, Perindopril, Trandfolapril, Captopril, Enalapril, Lisinopril, and Others (Ramipril, etc.), ), By Indication (Hypertension, Coronary Artery Disease, Heart Failure, Chronic Kidney Disease, Scleroderma, and Others (Migraine, etc.)), By Route of Administration (Oral and Injectable), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)

Published In : Dec 2023
Code : CMI2746
Pages :160
Formats :
Excel and PDF
Industry : Pharmaceutical

Angiotensin Converting Enzymes (ACE) Inhibitors MarketSize and Trends

The global angiotensin converting enzymes (ACE) inhibitors market size is projected to reach US$ 11,831.7 million by 2030, from US$ 8,070.5 million in 2023, at a CAGR of 5.6% during the forecast period 2023-2030.

Global Angiotensin Converting Enzymes (ACE) Inhibitors Market- Trends

Increasing Generic Competition: As many ACE inhibitors have reached or are approaching patent expiration, there is a growing presence of generic versions of these medications. This trend is driven by efforts to reduce healthcare costs and improve patient access to affordable treatment options. Pharmaceutical companies are adapting to this trend by focusing on the development of combination therapies, improved drug delivery systems, or seeking opportunities in emerging markets.
Focus on Cardiovascular Health: The emphasis on cardiovascular health and prevention is driving the adoption of ACE inhibitors as part of early intervention strategies. Increased awareness and educational efforts encourage individuals to monitor their blood pressure and seek medical care, creating a trend of earlier diagnosis and treatment of hypertension and related conditions.
Patient-Centered Care: There is a growing emphasis on patient-centered care in the management of hypertension and related conditions. Patients are taking a more active role in their healthcare decisions. This trend is influencing the development of ACE inhibitors with improved tolerability, reduced side effects, and more convenient dosing schedules to enhance patient satisfaction and adherence.
Patient Education and Adherence Support: Patient education and adherence support programs are becoming more prevalent in the management of hypertension and cardiovascular conditions. These programs aim to improve patients understanding of the importance of medication adherence and lifestyle modifications. Pharmaceutical companies are developing educational materials and digital tools to aid in patient engagement and adherence.